Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and the Japanese Foundation for Cancer Research (JFCR), the first and leading non-profit cancer research organization in Japan, today announced a strategic alliance to accelerate access to oncology clinical trials in Japan.
DURHAM, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world™s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
DURHAM, N.C., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world™s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
DURHAM, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world™s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets ...
Parexel, a CRO providing a full range of Phase I to IV clinical development services, and Partex, a digital pharma platform, entered a strategic alliance designed to leverage artificial intelligence (AI)-powered solutions to accelerate drug discovery and development for biopharmaceutical customers, and to de-risk portfolio assets.
DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the worlds largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Parexel Introduces Expert Series – New Medicines, Novel Insights
BOSTON, and Durham, N.C., June 16, 2022 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO), today announced the launch of its Community Alliance Network, a novel program further integrating clinical research into the community healthcare setting to better serve patients and in turn create further opportunity for increased diversity in clinical trials. CVS Health®, the leading health care solutions company, and Javara, the leading Integrated Research Organization, have joined the network as inaugural members, opening the door to community-based research sites and increasing access to new patient populations to support trial delivery for Parexel’s biopharmaceutical customers.
BOSTON & DURHAM, N.C.--(BUSINESS WIRE)--Parexel, a leading global clinical research organization (CRO), and n-Lorem, a nonprofit foundation, today announced a new partnership in support of n-Lorem’s effort to discover and provide experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1 to 30 patients worldwide) for free, for life. Parexel brings significant expertise to the partnership, having managed approximately 400 rare disease clinical studies over the past five years that contributed to 17 FDA drug approvals.